1,201 results found

The U.S. Federal Trade Commission issued final changes to the premerger notification rules that affect whether pharmaceutical companies must report certain proposed acquisitions of exclusive patent rights to the FTC and the Antitrust Division of the Department of Justice for antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

A case decided last month in the U.S. Court of Federal Claims serves as a reminder to any company that conducts research and development work for, or delivers software to, U.S. Government customers that proper marking of deliveries is essential to protecting intellectual property rights in the deliveries.

Implementers of standard essential patents (SEPs) continue to hold out in patent licensing discussions with SEP owners, including pursuing the cynical strategy of seeking anti-suit injunctions (ASIs).

In 2013, The DOJ and USPTO issued their first policy (2013 Policy) in a trilogy directed to SEP-licensing negotiations.

A patent license agreement's anti-assignment clause did not restrict the assignment of the licensed patent because it did not mention the patent expressly...

Tesla made news a few weeks ago by offering a "license" to their intellectual property.

The web 2.0 world continues to revolutionize the ways that companies do business.

In the years and days leading up to the seminal U.S. Supreme Court decision in MedImmune, Inc. v. Genetech, Inc., 549 U.S. 118 (2007), it was common for licensors of patents...

Wizards of the Coast, LLC ("WOTC" or "Wizards") and its parent company Hasbro, Inc. ("Hasbro") recently found themselves facing unexpected backlash from their attempt to modify an existing license agreement...

On July 3, the Court of Justice of the European Union in UsedSoft GmbH v. Oracle International Corp. held that a licensor of software made available for download over the Internet may not prevent the resale of perpetual licenses by its licensees.

A business relationship is just that: a relationship. It has phases like any other relationship, and takes effort from both parties to keep it functional.

Your CIO calls to tell you that the IT group has been working with a vendor to purchase and implement a new software system that will handle an important business function of your health system.

AI licensing in healthcare involves complex decisions about asset definition, control allocation, and accountability as models and data evolve. This white paper examines the practical contracting challenges that arise when AI models intersect with health data, exploring how organizations can structure agreements that account for messy datasets, model artifacts, and the reality that machine learning systems resist traditional ownership frameworks.

Two experienced pharma business development leaders from Novo Nordisk and Takeda reveal the multidisciplinary screening process that determines which biotech partnerships advance beyond initial evaluation. The discussion demystifies pharma's scouting methodology, partnership readiness requirements, and the critical factors that cause promising engagements to stall or succeed.

As with many industries, the insurance sector has become increasingly more complex and internationally connected over the past decade.

In patent-infringement litigation, a licensee will only have standing to sue without joining the patent owner if it is an exclusive licensee and it holds all substantial rights in the patent.

ROSS Intelligence set out to build an AI legal-research tool to compete with Westlaw. After Thomson Reuters declined to license Westlaw content, ROSS obtained training material through a third party: thousands of “bulk memos,” question-and-answer pairs that were built from Westlaw headnotes. ROSS used them to train its search tool. Thomson Reute